Evidence map›Paper›PMID 38169295›Full record

ArticleJournal of bacteriology2024

An

Kaitlyn E Barrack, Thomas H Hampton, Rebecca A Valls, Sarvesh V Surve, Timothy B Gardner, Julie L Sanville, Juliette L Madan, George A O'Toole

Open access · hybridAbstract read
In one paragraph

Article in Journal of bacteriology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kaitlyn E BarrackDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth , Hanover, New Hampshire, USA.
Thomas H HamptonDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth , Hanover, New Hampshire, USA.ORCID 0000-0003-0543-402X
Rebecca A VallsDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth , Hanover, New Hampshire, USA.
Sarvesh V SurveDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth , Hanover, New Hampshire, USA.
Timothy B GardnerSection of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center , Lebanon, New Hampshire, USA.
Julie L SanvilleDivision of Pediatric Gastroenterology, Department of Pediatrics, Dartmouth Hitchcock Medical Center , Lebanon, New Hampshire, USA.
Juliette L MadanDepartments of Psychiatry and Pediatrics, Dartmouth Hitchcock Medical Center , Lebanon, New Hampshire, USA.
George A O'TooleDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth , Hanover, New Hampshire, USA.ORCID 0000-0002-2861-4392
Dartmouth College · USDartmouth–Hitchcock Medical Center · US

Funding

Translational Research CoreP30DK117469 · NIDDK · DARTMOUTH COLLEGE · PI DEBORAH A HOGAN · 2018 to 2026
$13.9M
HOST-MICROBE INTERACTIONST32AI007519 · NIAID · DARTMOUTH COLLEGE · PI DEBORAH A HOGAN · 1997 to 2026
$5.9M
Dartmouth Cystic Fibrosis Training ProgramT32HL134598 · NHLBI · DARTMOUTH COLLEGE · PI George A. O'Toole · 2017 to 2026
$1.7M
Arsenic, the Microbiome & Health Outcomes: Mechanisms to Methods of InterventionR01ES033988 · NIEHS · DARTMOUTH COLLEGE · PI George A. O'Toole · 2023 to 2026
$1.6M
NHLBI NIH HHS T32 HL134598NIAID NIH HHS T32 AI007519NIDDK NIH HHS P30 DK117469NIEHS NIH HHS R01 ES033988
6 · The paper itself

Abstract

The gut physiology of pediatric and adult persons with cystic fibrosis (pwCF) is altered relative to healthy persons. The CF gut is characterized, in part, as having excess mucus, increased fat content, acidic pH, increased inflammation, increased antibiotic perturbation, and the potential for increased oxygen availability. These physiological differences shift nutritional availability and the local environment for intestinal microbes, thus likely driving significant changes in microbial metabolism, colonization, and competition with other microbes. The impact of any specific change in this physiological landscape is difficult to parse using human or animal studies. Thus, we have developed a novel culture medium representative of the CF gut environment, inclusive of all the aforementioned features. This medium, called CF-MiPro, maintains CF gut microbiome communities, while significantly shifting nonCF gut microbiome communities toward a CF-like microbial profile, characterized by low Bacteroidetes and high Proteobacteria abundance. This medium is able to maintain this culture composition for up to 5 days of passage. Additionally, microbial communities passaged in CF-MiPro produce significantly less immunomodulatory short-chain fatty acids (SCFA), including propionate and butyrate, than communities passaged in MiPro, a culture medium representative of healthy gut physiology, confirming not only a shift in microbial composition but also altered community function. Our results support the potential for this

Indexed as

Cystic FibrosisGastrointestinal MicrobiomeMicrobiotaAdultAnimalsChildCystic Fibrosis Transmembrane Conductance RegulatorDysbiosisHumansRespiratory SystemCystic Fibrosis Transmembrane Conductance Regulatorcolonoscopycystic fibrosisdysbiosismediumstool

Identifiers

PMID38169295
PMCPMC10810206
OpenAlexW4390545174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.